First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Status:
Recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
The aim of this first-in-human trial is to characterize the safety, tolerability,
pharmacokinetic (PK), and pharmacodynamic characteristics of GEN3009 (DuoHexabody®-CD37) in
subjects with relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL).